» Articles » PMID: 32595831

Increased CHST15 Follows Decline in Arylsulfatase B (ARSB) and Disinhibition of Non-canonical WNT Signaling: Potential Impact on Epithelial and Mesenchymal Identity

Overview
Journal Oncotarget
Specialty Oncology
Date 2020 Jun 30
PMID 32595831
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Expression of CHST15 (carbohydrate sulfotransferase 15; chondroitin 4-sulfate-6-sulfotransferase; BRAG), the sulfotransferase enzyme that adds 6-sulfate to chondroitin 4-sulfate (C4S) to make chondroitin 4,6-disulfate (chondroitin sulfate E, CSE), was increased in malignant prostate epithelium obtained by laser capture microdissection and following arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) silencing in human prostate epithelial cells. Experiments in normal and malignant human prostate epithelial and stromal cells and tissues, in HepG2 cells, and in the ARSB-null mouse were performed to determine the pathway by which CHST15 expression is up-regulated when ARSB expression is reduced. Effects of Wnt-containing prostate stromal cell spent media and selective inhibitors of WNT, JNK, p38, SHP2, β-catenin, Rho, and Rac-1 signaling pathways were determined. Activation of WNT signaling followed declines in ARSB and Dickkopf WNT Signaling Pathway Inhibitor (DKK)3 and was required for increased CHST15 expression. The increase in expression of CHST15 followed activation of non-canonical WNT signaling and involved Wnt3A, Rac-1 GTPase, phospho-p38 MAPK, and nuclear DNA-bound GATA-3. Inhibition of JNK, Sp1, β-catenin nuclear translocation, or Rho kinase had no effect. Consistent with higher expression of CHST15 in prostate epithelium, disaccharide analysis showed higher levels of CSE and chondroitin 6-sulfate (C6S) disaccharides in prostate epithelial cells. In contrast, chondroitin 4-sulfate (C4S) disaccharides were greater in prostate stromal cells. CSE may contribute to increased C4S in malignant epithelium when GALNS (N-aceytylgalactosamine-6-sulfate sulfatase) is increased and ARSB is reduced. These effects increase chondroitin 4-sulfates and reduce chondroitin 6-sulfates, consistent with enhanced stromal characteristics and epithelial-mesenchymal transition.

Citing Articles

Exogenous recombinant N-acetylgalactosamine-4-sulfatase (Arylsulfatase B; ARSB) inhibits progression of B16F10 cutaneous melanomas and modulates cell signaling.

Bhattacharyya S, O-Sullivan I, Tu J, Chen Z, Tobacman J Biochim Biophys Acta Mol Basis Dis. 2023; 1870(1):166913.

PMID: 37813168 PMC: 11265800. DOI: 10.1016/j.bbadis.2023.166913.


Carbohydrate sulfotransferases: a review of emerging diagnostic and prognostic applications.

Begolli G, Markovic I, Knezevic J, Debeljak Z Biochem Med (Zagreb). 2023; 33(3):030503.

PMID: 37545696 PMC: 10373059. DOI: 10.11613/BM.2023.030503.


Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases.

Tobacman J, Bhattacharyya S Int J Mol Sci. 2022; 23(21).

PMID: 36361933 PMC: 9654056. DOI: 10.3390/ijms232113146.


Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction.

Blake M, Parrish D, Staffenson M, Sueda S, Woodward W, Habecker B Elife. 2022; 11.

PMID: 35604022 PMC: 9197393. DOI: 10.7554/eLife.78387.


Transcriptome analysis of tumor-derived mesenchymal progenitor cells shows that is a fibrosis regulator of retroperitoneal liposarcoma.

Sun Y, Xiao F, Sun H, Zhang L, Chen W, Du L Ann Transl Med. 2022; 10(6):360.

PMID: 35434026 PMC: 9011283. DOI: 10.21037/atm-22-963.


References
1.
Bhattacharyya S, Feferman L, Tobacman J . Inhibition of Phosphatase Activity Follows Decline in Sulfatase Activity and Leads to Transcriptional Effects through Sustained Phosphorylation of Transcription Factor MITF. PLoS One. 2016; 11(4):e0153463. PMC: 4831796. DOI: 10.1371/journal.pone.0153463. View

2.
Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth B, Remm M . Primer3--new capabilities and interfaces. Nucleic Acids Res. 2012; 40(15):e115. PMC: 3424584. DOI: 10.1093/nar/gks596. View

3.
Bhattacharyya S, Feferman L, Tobacman J . Arylsulfatase B regulates versican expression by galectin-3 and AP-1 mediated transcriptional effects. Oncogene. 2013; 33(47):5467-76. PMC: 4024465. DOI: 10.1038/onc.2013.483. View

4.
Bhattacharyya S, Feferman L, Terai K, Dudek A, Tobacman J . Decline in arylsulfatase B leads to increased invasiveness of melanoma cells. Oncotarget. 2016; 8(3):4169-4180. PMC: 5354821. DOI: 10.18632/oncotarget.13751. View

5.
Bhattacharyya S, Feferman L, Tobacman J . Regulation of chondroitin-4-sulfotransferase (CHST11) expression by opposing effects of arylsulfatase B on BMP4 and Wnt9A. Biochim Biophys Acta. 2014; 1849(3):342-52. PMC: 4336629. DOI: 10.1016/j.bbagrm.2014.12.009. View